Use of Intravitreal Steroids in the Clinic

Retina Today

Volumn , Issue JUNE SUPPL., 2010, Pages 6-10

  Morse, Lawrence S ^a   Modjtahedi, Sara ^b   Smit McBride, Zeljka ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82255189662     PISSN: None     EISSN: 18250572     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert Opin Pharmacother. 2009;10(15):2511-2525.
2. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 115:1447-1449, 49 e1-10.
3. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127:1115-1128.
4. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE. Triamcinolone acetonide inhibits IL-6-and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci. 2006;47: 4935-4941.
5. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139-149.
6. Cidlowski JA. Glucocorticoids and their actions in cells. Retina. 2008;29:S21-S23.
7. Smit-McBride Z. Gene profiling of early and late induced changes in gene expression upon intravitreal injection of triamcinolone and dexamethasone in the mouse retina. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; May 2009; Fort Lauderdale, FL.
8. Modjtahedi SP. Immmunoregulatory Gene profiling of early and late induced changes in retinal gene expression after intravitreal steroid injections in mice. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; May 2010; Fort Lauderdale, FL.
9. Augustin A. Triple therapy for age-related macular degeneration. Retina. 2009;29:S8-S11.
10. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina. 2009;29:573-578.
11. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol. 2009;93(6):754-758.
12. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010;27(2):117-134.
13. Chong DY, Boehlke CS, Zheng QD, Zhang L, Han Y, Zacks DN. Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. 2008;49: 3193-3200.
14. Itoi K, Nakamura K, Oku H, Ishizaki E, et al. Relationship between diabetic macular edema and peripheral Th1/Th2 balance. Ophthalmologica. 2008;222(4):249-253.
15. Huang P, Zhang SS, Zhang C. Erratum: The two sides of cytokine signaling and glaucomatous optic neuropathy. J Ocul Biol Dis Infor. 2009;2(3):98-103.
16. Huang P, Zhang SS, Zhang C. The two sides of cytokine signaling and glaucomatous optic neuropathy. J Ocul Biol Dis Infor. 2009;2(2):78-83.
17. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158.